Objective To study the clinical efficacy and influence on the immune function of Shenmai injection combined with bronchial artery interventional chemotherapy for treating advanced lung cancer. Methods Sixty patients with pathologically and radiologi-cally confirmed advanced lung cancer were randomly divided into control group and observation group, each group with 30 cases. Control goup received bronchial artery interventional chemotherapy, and observation group was treated with Shenmai injection combined with bronchial artery interventional chemotherapy. The clinical effects, survival rate and toxicity response were observed in two goups, the serum T-lymphocyte subsets levels of CD3+ , CD4+ , CD8+ , CD4+ /CD8+ , NK cell were estimated with flow cytometry. Results Short-term response rate (76. 67% ) ,1,2 year-survival rate (86. 67% ,46. 67% ) in observation group were significantly higher than those in control group (60. 00% ,73. 33% ,33. 33% ,respectively) (P <0. 05). Toxicity response in the observation group was significantly lower than that in the control goup (P < 0. 05). No significant difference in serum levels of T cell subsets existed between two goups before the treatment ( P >0. 05). Howerver, CD3+ , CD4+ , CD4*/CDg+ , NK cell level in observation group after the treatment were significanltly higher than those in control group (P < 0. 05 ) . Conclusions Shenmai injection combined with bronchial artery interventional chemotherapy for treating advanced lung cancer could improve clinical efficacy, reduce side effects, and enhance immune function.%目的 探讨参麦注射液辅助支气管动脉介入化疗治疗中晚期肺癌的临床效果和对免疫功能的影响.方法 60例中晚期肺癌患者随机分为对照组和观察组,每组30例,两组采用支气管动脉介入化疗,观察组在对照组的基础上应用参麦注射液.观察两组近远期疗效、副作用以及血清中T细胞亚群CD3+、CD4+、CD8+、CD+4/CD8+、NK的水平.结果 观察组近期有效率、1年生存率、2年生存率分别为76.67％、86.67％、46.67％,明显高于对照组的60.00％、73.33％、33.33％,P＜0.05;观察组的毒副反应发生率显著低于对照组,P＜0.05;治疗前两组T细胞亚群水平无明显差异,P＞0.05,治疗8周后观察组的CD3+、CD4+、CD;/CD8+、NK水平较治疗前显著上升,且明显高于对照组,P＜0.05,而对照组与治疗前比较无统计学差异,P＞0.05.结论 参麦注射液辅助支气管动脉介入治疗中晚期肺癌显著改善临床效果,降低毒副作用.
展开▼
